HHS Supporting Clinical Study of Zika Virus Blood Screening Test

"BARDA staff has worked closely with our partners at FDA and the Office of the Assistant Secretary of Health to ensure the continuity and safety of the U.S. blood supply," said Dr. Richard Hatchett, BARDA's acting director. "Today's award to Roche is an important step towards securing the safety of the blood supply in Puerto Rico and in the rest of the United States."

  • Apr 25, 2016

The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Office of the Assistant Secretary for Health are supporting the development of a test to identify whether donated blood is infected with the Zika virus, HHS announced April 22, reporting that ASPR's Biomedical Advanced Research and Development Authority, known as BARDA, agreed that day to support a clinical study to evaluate the sensitivity and specificity of the blood donation screening test in its actual use. This study is necessary to apply for FDA approval for commercial marketing.

The test is manufactured by Roche Molecular Systems, Inc., which is based in Branchburg, N.J.

"BARDA staff has worked closely with our partners at FDA and the Office of the Assistant Secretary of Health to ensure the continuity and safety of the U.S. blood supply," said Dr. Richard Hatchett, BARDA's acting director. "Today's award to Roche is an important step towards securing the safety of the blood supply in Puerto Rico and in the rest of the United States."

According to HHS, most people infected with Zika do not have symptoms and may donate blood not knowing that they are infected. And there have been reports of probable cases of transfusion transmission of Zika virus in Brazil that are being investigated. So having an accurate blood donation screening test will help to ensure that infected blood is removed from the blood supply.

Under a one-year, $354,500 contract, Roche will study blood samples to confirm whether the test accurately and reliably detects and identifies Zika virus, even when present in a very low concentration in a donor's blood.

Product Showcase

  • The MGC Simple Plus

    The MGC Simple Plus is a simple-to-use, portable multi gas detector that runs continuously for three years without being recharged or routinely calibrated after its initial charge and calibration during manufacturing. The detector reliably tests a worksite’s atmosphere for hydrogen sulfide, carbon monoxide, oxygen and combustible gases (LEL). Its durability enables the detector to withstand the harshest treatment and environments, hence earning it an IP 68 rating. The MGC Simple Plus is also compatible with a variety of accessories, such as the GCT External Pump. Visit gascliptech.com for more information. Read More

  • Full Line of Defense Against Combustible Dust Nilfisk

    Nilfisk provides a comprehensive range of industrial vacuums meticulously crafted to adhere to NFPA 652 housekeeping standards, essential for gathering combustible dust in Class I, Group D, and Class II, Groups E, F & G environments or non-classified settings. Our pneumatic vacuums are meticulously engineered to fulfill safety criteria for deployment in hazardous surroundings. Leveraging advanced filtration technology, Nilfisk ensures the secure capture of combustible materials scattered throughout your facility, ranging from fuels, solvents, and metal dust to flour, sugar, and pharmaceutical powders. Read More

  • SwabTek® Cannabis Test Kit

    The SwabTek® Cannabis Test Kit is a single-use spot test designed for use in screening for cannabis compounds in any sample type or on any surface. The test is capable of identifying the presumed presence of cannabinoids in very small quantities, with a level of detection as little as 6 μg in mass. Learn more about the SwabTek® Cannabis Test Kit and the rest of SwabTek surface drug testing solutions through the webinar titled "Everything You Want To Know About Surface Testing" Read More

Featured

Most   Popular

Artificial Intelligence